A comprehensive transcriptomic and biochemical evaluation of a differentiation inducing anti-leukemic principle isolated from Momordica charantia

Abstract

Deep exome resequencing is a powerful approach for delineating patterns of protein-coding variation among genes, pathways, individuals and populations. We analyzed exome data from 2,440 individuals of European and African ancestry as part of the National Heart, Lung, and Blood Institute's Exome Project, the aim of which is to discover novel genes and mechanisms that contribute to heart, lung and blood disorders. Each exome was sequenced to a mean coverage of 116×, allowing detailed inferences about the population genomic patterns of both common variation and rare coding variation. We identifi ed more than 500,000 single nucleotide variations, the majority of which were novel and rare (76% of variants had a minor allele frequency of less than 0.1%), refl ecting the recent dramatic increase in the size of the human population. The unprecedented magnitude of this dataset allowed us to rigorously characterize the large variation in nucleotide diversity among genes (ranging from 0 to 1.32%), as well as the role of positive and purifying selection in shaping patterns of proteincoding variation and the diff erential signatures of population structure from rare and common variation. This dataset provides a framework for personal genomics and is an important resource that will allow inferences of broad importance to human evolution and health. I2Abstract not submitted for online publication. I3Are clinical genomes already becoming semi-routine for patient care? Mark Boguski Harvard Medical School, Boston, MA, USA Genome Biology 2011, 12(Suppl 1):I16 Hardly a month goes by without a new published report of a patient's genome being used diagnostically for clinical management in a diverse spectrum of disease areas, including gastroenterology, nephrology, neurology and oncology. The impression is that clinical genomics is already becoming semiroutine. However, a large and complex set of non-technical barriers needs to be overcome before genomics can truly be integrated into the practice of medicine and made widely available for patient care. Through the use of case studies, my presentation will elucidate issues relating to the needs and requirements of the workforce, the legal and regulatory aspects of 'laboratorydeveloped tests' and insurance reimbursement for 'multi-analyte diagnostics' . The roles of the Food and Drug Administration, the Centers for Medicare & Medicaid Services and the College of American Pathologists will be highlighted. I4Interrogating the architecture of cancer genomes Peter Campbell Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK Genome Biology 2011, 12(Suppl 1):I11Cancer is driven by mutation. Using massively parallel sequencing technology, we can now sequence the entire genome of cancer samples, allowing the generation of comprehensive catalogs of somatic mutations of all classes. Bespoke algorithms have been developed to identify somatically acquired point mutations, copy number changes and genomic rearrangements, which require extensive validation by confi rmatory testing. The ...